Case Study: Bristol Myers Squibb achieves faster site selection and activation with Veeva Systems

Bristol Myers Squibb Accelerates Site Start-Up with Data-Driven Feasibility & Activation

Bristol Myers Squibb (BMS) faced a challenge with fragmented feasibility data and document-heavy site start-up processes that made it hard to validate site estimates, reuse historical insights, and keep investigator sites from repeating the same work across multiple studies. The company needed a more efficient, centralized approach to feasibility and activation, and turned to Veeva Systems and its Veeva Clinical Operations, including Veeva CTMS and Veeva Study Startup.

Veeva Systems helped BMS consolidate feasibility data into a single system, automate workflows, and replace manual trackers with standardized templates and real-time dashboards. The results included a 33% faster site selection and activation process, six weeks shaved off the time from protocol approval to first patient in/first subject dosed, and an anticipated 50% reduction in time to complete feasibility surveys.

Bristol Myers Squibb

Mano Das

Director IT